Videos

The director of the Powell Gene Therapy Center at the University of Florida discussed the importance of Rare Disease Day.

The professor of ophthalmology from Radboud University, The Netherlands, discussed ongoing gene therapy trials in Stargardt disease.

The chief scientific officer and senior vice president of the Parkinson’s Foundation discussed the organization’s initiative to advance genetic testing.

The director of the hemostasis and thrombosis program at Children’s Hospital Los Angeles discussed mitigation strategies in trials and clinic.

The director of the Pediatric Hemophilia and Coagulation Disorders Program at CS Mott Children’s Hospital discussed the advantages of AAV gene therapies.

The chief scientific officer of FibroBiologics discussed the benefits of fibroblast cell technology in MS.

The ophthalmologist from John A. Moran Eye Center discussed the close association between disease progression and uncovered risk alleles.

Matthew Gantz, president and chief executive officer, Castle Creek Biosciences, discussed FCX-013 for the potential treatment of scleroderma.

The global head of research and development at Atara Biotherapeutics discussed the link between EBV and MS.

The director of research and development at AVROBIO discussed the analytical pipeline the company has developed for molecular follow-up of cell therapies.

The associate professor from UC San Diego discussed the curative potential of gene therapy in cystinosis.

The translational immunologist and research professor at Perelman School of Medicine, University of Pennsylvania, discussed persistence of CD4+ CAR T-cells in CLL.

The associate professor from Tufts University School of Medicine discussed the latest updates on the FOCUS trial.

The senior vice president of clinical development at Passage Bio discussed new data from the IMAGINE-1 trial presented at WORLDSymposium.

The chief scientific officer of FibroBiologics discussed the advantages of fibroblast cell therapy over stem cell therapy.

The hematologist/oncologist from Mayo Clinic discussed targeting HLA loss in solid tumors.

Dolores Schendel, PhD, chief executive and chief scientific officer, Medigene, discussed the company’s collaboration with 2seventy bio to develop TCR T-cell therapies.

The professor and head of coagulation disorders and Comprehensive Care Centre, University Hospital of Frankfurt, Germany, discussed results of the final analysis of the HOPE-B study.

The director of the hemostasis and thrombosis program at Children’s Hospital Los Angeles discussed the ATLAS-INH trial.

The director of the Pediatric Hemophilia and Coagulation Disorders Program at CS Mott Children’s Hospital discussed challenges in hemophilia A and B.

Matthew Gantz, president and chief executive officer, Castle Creek Biosciences, discussed the company and its pipeline.

The director of the Melanoma Program at Cedars-Sinai Medical Center discussed the efficacy of TIL therapy following immunotherapy in advanced melanoma.

Experts discussed the ZUMA-2 clinical trial of brexucabtagene autoleucel.

The director of the Melanoma Program at Cedars-Sinai Medical Center discussed evaluation criteria for TIL therapy in melanoma.

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed data from both the CARTITUDE-1 and CARTITUDE-2 studies.

The medical director of Bone Marrow Transplantation and Immune Deficiency at Cincinnati Children's discussed data on ARU-1801 presented at ASH 2021.

The hematologist/oncologist from Mayo Clinic discussed advantages of Tmod cell therapy in solid tumors.

Dolores Schendel, PhD, chief executive and chief scientific officer, Medigene, discussed MDG1011 and Medigene’s future research and targets.